Article de revue

Cancer-salient messaging for Human Papillomavirus vaccine uptake: A randomized controlled trial

Vaccination with Human Papillomavirus (HPV) vaccine is recommended for 11–12 years-old, but uptake is suboptimal. Current messaging focuses on HPV infection transmission and prevention. Parents and providers are often uncomfortable discussing sexual practices of adolescents, contributing to the delay/refusal of vaccine. We created a cervical cancer-salient message encouraging HPV vaccination, emphasizing disease salience and disease threat, while promoting self-efficacy. We hypothesized this message would have greater effects on vaccine confidence and intent to vaccinate compared to Centers for Disease Control and Prevention (CDC) and non-vaccine control messages

Langues

  • Anglais

Année de publication

2018

Journal

Vaccine

Volume

36

Numéro

18

Type

Article de revue

Catégories

  • Prestation de services

Maladies

  • Papillomavirus humain

Mots-clés

  • Suivi de la couverture
  • Introduction de nouveaux vaccins

Ajouté par: Moderator

Ajouté le: 2018-04-19 07:43:43

Consultations: 1364